World Intracranial Pressure Monitors Market expected to reach US$1.63 bn by the end of the forecast period
Traumatic brain injuries and strokes remain one of the leading causes of death and disability across the globe. The upswing in the cases of brain injuries in adults as well as children has proved to be a shot in the arm for the global intracranial pressure monitors market. The Centers for Disease Control and Prevention states that every day nearly 140 people in the U.S. die from injuries that are associated with traumatic brain injuries.
According to a report by Transparency Market Research (TMR), the opportunity in the global intracranial pressure monitors market was pegged at US$0.94 bn in 2014 and is poised to reach US$1.63 bn by 2023, rising at a CAGR of 6.30% between 2015 and 2023. A TMR analyst states that the sweeping shift towards non-invasive pressure monitors from invasive ones is likely to have a positive and enduring impact on the dynamics of the market.
How are governments playing an important role in the growth of the global intracranial pressure monitors market?
Governments across the world are raising their budgets for the healthcare development. For instance, the Centers for Medicare and Medicaid Services revealed that the U.S. government had increased the bar for healthcare spending from 3.6% in 2013 to 5% in 2014. Other developed countries such as France, Japan, and Germany are also increasing their healthcare spending every year. France’s healthcare system covers the public-private mix of hospital and ambulatory care with a higher volume of service provisions as compared to the U.S. Emerging countries such as India, China, and the Philippines are also jumping on the bandwagon, thereby providing a boost to the overall intracranial pressure monitors market.
How are developed regions contributing to the growth of the global intracranial pressure monitors market?
North America will continue to dominate the market in terms of revenue until 2023, followed by Europe. The rising incidence of traumatic injuries and neurological disorders are boosting the demand for intracranial pressure monitors in these regions. In addition, the rapid technological advancements in the field of pressure monitoring are anticipated to provide a fillip to these regional markets as well as the global market.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6445
Why are manufacturers in the global intracranial pressure monitors market shifting focus towards emerging markets?
Despite the dominance of North America, Asia Pacific will offer substantial lucrative opportunities to market players, owing to the presence of numerous untapped markets. Over the past few years, the cases of cerebrovascular disorders have recorded a sudden rise, primarily due to the growing aging population in this region. Moreover, the consumer expenditure on healthcare has increased, thanks to the rising disposable income. Owing to these factors, the Asia Pacific market for intracranial pressure monitors is estimated to expand at a significant CAGR during the forecast period.
The leading companies operating in the anti-snoring devices and snoring surgery market have been focusing on product innovation and miniaturization of sleep apnea devices. This is a novel trend swaying the global anti-snoring devices and snoring surgery market. Integrated by the nanotechnology, this trend could be a major determinant for the market’s growth. Currently, the market is exhibiting a strong focus on innovation, as per a new study by Transparency Market Research. Efforts by new and existing players have resulted in the development of an impressive pipeline of products that are expected to help find better cure for people suffering from sleep apnea.
Q: What strategies are the leading market players adopting to gain stronghold?
A: The global anti-snoring devices and snoring surgery market is marked by the presence of an increasing number of companies which has rendered its vendor landscape highly competitive and fragmented. TMR finds that enterprises such as Medtronic plc, Philips Healthcare, GE Healthcare, Fisher & Paykel Healthcare, and ResMed, Inc are not only leading market participant but also hold significant share in the global market with their robust geographic reach and extensive product portfolio.
Of these, Medtronic has managed emerging dominant in the overall market following a slew of recent acquisitions. Medtronic along with Phillips Healthcare and GE healthcare are the top players in the market, contributing a whopping 93.69% of the overall revenue generated by the market. In order to accelerate their pace of gains, a majority of the leading companies operating in the anti-snoring devices and snoring surgery market are investing in research and development activities.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6910
Besides this they are also focusing on product innovation to strengthen their position in the market. For instance, an Australian company has recently launched a 3D printed anti-snoring device that can be customized based on an individual’s need. The medical device company is called Oventus Medical and is based in Melbourne, Australia. It is set to manufacture a device they named O2Vent. It is a lightweight titanium devices and can help patients stop snoring by delivering air to the back of his or her mouth. Such innovations hold great promise of the company success in the market
Q: Which region will offer most lucrative opportunities to the market?
A: North America and Europe together dominated the global anti-soring devices and snoring surgery market in 2015. While these are mature markets, the opportunities existing in Asia Pacific is also expected to prove quite lucrative for companies manufacturing anti-snoring devices. Because the region is characterized by presence of unmet medical needs and high patient pool it is expected to attract several of the small or medium scale companies and new entrants looking to establish their footprint in the market. In addition favorable government initiatives to spread awareness about sleep apnea and its possible treatments will also support the market’s strong growth in Asia Pacific.
Clostridium Vaccine (Animal Health) Market: Short Product Exclusivity Span to Foster Growth of Generics
The global clostridium vaccine (animal health) market features a largely consolidated competitive landscape, with the top five companies collectively accounting for a share of over 63% of the overall market in 2015, observes a recent report by Transparency Market Research (TMR). These top vendors, namely Zoetis, Inc., Merck & Co., Sanofi-Aventis, Boehringer Ingelheim, and Eli Lilly and Company hold commanding positions owing to their wide geographic presence and a strong financial backing allowing increased focus on research and development activities.
Top companies in the market aim to strengthen their positions with strategies such as targeted in-licensing, acquisition, and innovative marketing. Use of the digital medium to reach out to an extended consumer base and serve the consumer more effectively has also started becoming a popular strategy. An instance is the recent update made to Bayer’s BCS cowdition smartphone application in July 2016. The enhanced application is expected to help veterinarians to track the current and future hurdles regarding cattle health, which will help minimize the impact of metabolic diseases on dairy cows.
Transparency Market Research estimates that the global clostridium vaccines market will exhibit a healthy 4.9% CAGR over the period between 2016 and 2024. Rising at this rate, the market, which valued at US$418.0 mn in 2015, is expected to reach US$643.5 mn by 2024. In terms of animal species, the swine segment presently leads but is expected to be outpaced by the growth of the ovine segment. In terms of geography, the global market is dominated by North America, which accounted for over 37% of the global market in 2015.
Rising Intervention by Government Bodies to Play Key Role in Market Development
Government initiatives play a key role the development of animal health care markets. For instance, the China market for veterinary healthcare is chiefly driven by compulsory immunization policy, several animal health awareness programs, the easy availability of affordable veterinary vaccines, and fund for research and development in the field. In several other developed as well as developing economies, funds invested by government bodies for the research and development of veterinary vaccines and medications play a key role in boosting the demand for clostridium vaccines.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16682
Along with this, the rising global demand for animal products such as cattle milk, meat, and eggs is also a key factor driving the global market for clostridium vaccines. Animal products such as milk, pork, beef, and chicken collectively account for nearly 40% of global agricultural GDP and generated revenues valuing nearly US$600 bn in 2015. The market for these products in developing countries is growing rapidly due to the rising population and increased disposable incomes. The resultant rise in awareness regarding the need for maintaining the excellent health of animals is expected to further drive the clostridium vaccines market in the near future.
High Consumer Dependence on Government Distribution Channels to Hamper Growth
In emerging economies, especially, government bodies play the central role in the distribution of vaccines. The Government of India, for instance, buys clostridium vaccines in bulk from manufacturers and supply them in different regions of the country. Bulk purchase of clostridium vaccines results in reduced prices, resulting in the low profitability of the market thus hampering its overall rate of development.
Moreover, the market’s growth is also restrained to vast extent owing to the short exclusivity span of clostridium vaccines. Product exclusivity period in the animal health care industry is mostly only about three years to five years. Shorter exclusivity periods lead to a vast rise in competition from generics and over-the-counter (OTC) products. The increase in generic competition lowers product sales and significantly affects the profitability of the market.
This review of the market is based on a recent market research report published by Transparency Market Research, titled “Clostridium Vaccine (Animal Health) Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024.”
Cardiac Output Monitoring Devices Market: Growing ageing population, and raising healthcare infrastructure facilities are the growth drivers of this market
Cardiac output is known as the volume of blood is pumped by from the right or left ventricle of heart per minute and which is dependent on heart rate, and stroke volume. The cardiac output increases during acute exercise and mental stress, while decreased cardiac output might include physical exercise of a intensity that the patient is not able to bear because of decrease in oxygen supply, obesity, ingestion of large meals that place an added workload on the heart, retention of fluid, emotional stress, hypervolemia, and smoking. It is essential to assess the state of patient’s blood circulation. Low cardiac output usually leads to a common problem of low blood pressure which might surface occur during surgery, or during postoperative care in the intensive care units.
In high-risk surgical patients and critically ill patients the arterial blood pressure and cardiac output usually are monitored more comprehensively. Cardiac output monitoring devices are used to know the cardiac output of heart and arterial oxygen content which enable the circulation of continuous systemic oxygen supply to the body. Doubling the cardiac output leads to double amount of the oxygen supply to the tissues, while the low cardiac output leads to inadequate supply of oxygen to organs like brain and the low amount of cellular oxygenation can cause tissue and organ failure. The major observed causative factors for the decrease cardiac output are congenital heart defects, pathologic changes in the heart’s muscle, blood dyscrasias, chronic pulmonary disease and electrolyte imbalances (as of potassium or calcium). According to North American Nursing Diagnosis Association, decreased cardiac output is defined as a state in which inadequate blood is pumped by the heart to meet the metabolic demands of the body. Cardiac output monitoring devices market is classified on the basis of product type, methods, end-user and geography.
On the basis of product type the market is broadly classified into invasive, minimally-invasive and non-invasive cardiac output monitoring devices. The invasive cardiac output monitoring has been traditionally accomplished using the pulmonary artery catheter (PAC), but complications associated with PAC has markedly decreased the widespread use of the PAC. The market demand for the non- invasive devices is high followed by minimally invasive devices as compare to invasive devices, due to factors such as ease, accessibility and cost- effectiveness and fast response time. By methods the market is segmented as thermodilution method, pulse pressure analysis, Doppler method, bioimpedance and applied Fick principle. Each methods has its own merits and demerits. On the basis of end-user the market is segmented as hospitals, ambulatory care and critical care centers. By end-user hospitals covers the major market for cardiac output monitoring devices, because of reliability and conjunction of other therapeutic treatments. The factors such as raising incidences of cardiovascular diseases, increase in the number of people suffering from obesity, growing ageing population, and raising healthcare infrastructure facilities are the growth drivers of this market.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14153
By geography, the market can be segmented into North America, Europe, Asia Pacific, and Rest of the world. Geographically, North America was observed to have the major share of cardiac output monitoring device market due to high healthcare awareness, prevalence of cardiovascular diseases and technological advancement in the region. Europe contributes to the second largest share in the cardiac output monitoring device market growth with raising ageing population. However, Asia Pacific region is expected to be the fastest growing due to the gradual adoption of improved technologies, emerging health care infrastructures, and raising population with cardiac problems and obesity. Followed by Rest of the world.
The major key players operating in cardiac output monitoring device market include Edwards Lifesciences Corporation, Cheetah Medical, PULSION Medical Systems SE, Philips Healthcare, LiDCO Group plc, Boston Scientific Corporation, GE Healthcare, and others. Bioreactance-based NICOM Cheetah Medical remains the topmost non-invasive market leader.
The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.
The global pharmacovigilance market has been responding to a high demand from the healthcare industry, achieving a CAGR of 14.2% between 2014 and 2020. This market was valued at US$2.42 bn in 2012. Owing to its strong growth rate, the market is expected to reach around US$6.1 bn before the end of 2020.Transparency Market Research has released a research report stating these statistics. The report is titled “Pharmacovigilance Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020,” and is expected to impart the most up-to-date knowledge to a user regarding this market.
Pharmacovigilance is a broad term of classification for various aspects of drug safety. It is the science of detecting, monitoring, and curing the negative effects of consuming too many drugs, thereby reducing or negating the side effects and immediate drawbacks of pharmaceutical products.
According to the report, the global pharmacovigilance market is currently being driven by a sharp rise in the number of drug overuse conditions. A growing number of drug toxicity cases are being reported, increasing the demand for pharmacovigilance services.
Read Full Report: http://www.transparencymarketresearch.com/pharmacovigilance-market.html
Additionally, the global pharmacovigilance market is also being fueled by a steadily increasing need from the pharmaceuticals industry to claim negative drug interactions and drug disasters at an earlier stage. This demand, combined with the growing public safety concern over the use of OTC drugs and others has had a visible impact on the global pharmacovigilance market.
The report divides the global pharmacovigilance market on the basis of drug development phase, methods, services, and geography.
On the basis of drug development phases, the global pharmacovigilance market is segmented into Phase I, Phase II, Phase III, and Phase IV/Post Marketing Surveillance. Over 60% of the market was occupied by Phase IV in 2013. Phase IV deal with a systematic and dynamic data collection process, and a marketed drug’s data interpretation. The report, however, expects Phase III to show the fastest growth rate within the given forecast period owing to a greater need for its factors. These include formulation of comparative safety data, study of errors in medication, and drug assessment during development stages.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1729
Spontaneous reporting was the leading method in the global pharmacovigilance market for 2013, and the market analysts believe it will exhibit a steady CAGR for the given forecast period. Its growth rate is attributed to the discovery of drug effects that were previously unknown for existing drugs. This method is also the cheapest one, adding to its preference by medical personnel.
The key players in the global pharmacovigilance market, as described in the report, include Wipro Limited, Novartis International AG, GlaxoSmithKline Plc., Pharmaceutical Product Development, LLC, (PPD), F. Hoffmann-La Roche Ltd., Accenture Plc., Cognizant Technology Solutions, Covance, Inc., Quintiles Transnational Holdings, Inc., and PAREXEL International Corporation.